PharmaCyte Biotech, Inc.(PMCB)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-04-30.

PharmaCyte Biotech, Inc. (PMCB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PMCB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Top institutional holders of PMCB by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. PMCB trades on the Nasdaq exchange and files with the SEC under CIK 1157075. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMCB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PharmaCyte Biotech, Inc. directly from SEC EDGAR.